Stem Cell Ophthalmology Treatment Study II
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Age - Related Macular Degeneration
- Blindness
- Glaucoma
- Stargardt Disease
- Vision Loss Night
- Vision, Low
- Leber Hereditary Optic Neuropathy
- Vision Loss Partial
- Macular Degeneration
- Maculopathy
- Nonarteritic Ischemic Optic Neuropathy
- Optic Atrophy
- Retinal Disease
- Retinopathy
- Optic Nerve Disease
- Retinitis Pigmentosa
- Optic Neuropathy
- Retina Atrophy
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Eyes with loss of vision from retinal or optic nerve conditions generally considered irreversible will be treated with a combination of injections of autologous bone marrow derived stem cells isolated from the bone marrow using standard medical and surgical practices. Retinal conditions may include ...
Eyes with loss of vision from retinal or optic nerve conditions generally considered irreversible will be treated with a combination of injections of autologous bone marrow derived stem cells isolated from the bone marrow using standard medical and surgical practices. Retinal conditions may include degenerative, ischemic or physical damage ( examples may include macular degeneration, hereditary retinal dystrophies such as retinitis pigmentosa, stargardt, non-perfusion retinopathies, post retinal detachment. Optic Nerve conditions may include degenerative, ischemic or physical damage ( examples may include optic nerve damage from glaucoma, compression, ischemic optic neuropathy, optic atrophy ). Injections may include retrobulbar, subtenon, intravitreal, intraocular, subretinal and intravenous. Patients will be followed for 12 months with serial comprehensive eye examinations including relevant imaging and diagnostic ophthalmic testing.
Tracking Information
- NCT #
- NCT03011541
- Collaborators
- Not Provided
- Investigators
- Study Chair: Steven Levy, MD MD Stem Cells Principal Investigator: Jeffrey Weiss, MD Coral Springs
Get Well Soon